The Pharma Data

DECEMBER 14, 2020

engine along with algorithms tuned to predict BBB permeability played an important role in helping determine which CNS cancers and which genomically-defined subtypes of CNS cancer should be prioritized for development. . We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I.

Drugs 52

Drugs Genomics Genome DNA 52

The Pharma Data

FEBRUARY 25, 2022

Several FDA-approved drugs – including for type 2 diabetes, hepatitis C and HIV – significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. Pfizer’s COVID-19 therapy Paxlovid, for example, targets Mpro.

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

The Pharma Data

OCTOBER 26, 2021

The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science. Cancer is a disease of the genome and treatment no longer depends solely on the tissue of origin.

Genome 52

Genome Genomics Research Medicine 52

XTalks

DECEMBER 11, 2023

Through the utilization of their state-of-the-art technology and substantial investments in research and development (R&D), these med tech/medical device companies persist in driving industry innovation beyond the pandemic, thereby laying the foundation for a more streamlined approach against diseases in the future.

Production 98

Production Sales In-Vitro Development 98

The Pharma Data

JANUARY 11, 2021

Dalcetrapib is a potential anti-viral treatment that binds to the catalytic site of 3CLMpro of SARS-CoV-2 in vitro. Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of SARS-CoV-2 samples. News information is not all-inclusive and updates are published once a week on Tuesdays. . . Diagnostics.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 9, 2021

Roche (SIX RO, ROG; OTCQX RHHBY) now posted that gantenerumab, ananti-amyloid beta antibody developed for subcutaneous administration, has been granted Improvement Rectifier Designation by theU.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice).

Antibody 52

Antibody In-Vitro Trials Development 52

The Pharma Data

OCTOBER 14, 2021

This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of AD, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies. Roche’s Chief Medical Officer and Head of Global Product Development.

Antibody 52

Antibody Medicine In-Vitro Trials 52

The Pharma Data

NOVEMBER 23, 2021

1 POLARIX is being conducted in collaboration with The Lymphoma Study Association (LYSA) and The Lymphoma Academic Research Organisation (LYSARC). Roche moment blazoned that new data from its expansive haematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021.

Antibody 52

Antibody In-Vitro Development Genomics 52

XTalks

AUGUST 12, 2020

Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.

RNA 52

RNA Protein DNA In-Vivo 52

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The same webinar held a Q&A session with Dr. Bahassi and two other experts from Medpace, Dr. Lyon L.

Clinical Trials 96

Clinical Trials Clinical Trials Trials FDA Approval 96

The Pharma Data

MARCH 16, 2021

The test runs on widely used high-throughput systems and is for research purposes only. 1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission.

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

The Pharma Data

DECEMBER 2, 2020

Progenity expects to use the net proceeds from the offering to support its operations, to invest in its molecular testing research and development program, to invest in research and development with respect to its precision medicine platform and for working capital and general corporate purposes. SAN DIEGO, Dec. About Progenity.

In-Vitro 40

In-Vitro Sales Containment Development 40

The Pharma Data

DECEMBER 2, 2020

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. NASDAQ: PROG) today announced the pricing of its offering of $75.0 The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. million principal amount of notes. per share of common stock.

Sales 40

Sales In-Vitro Containment Development 40

Roots Analysis

AUGUST 12, 2024

Molecular diagnostic tests are advanced techniques and tools used to analyze biological markers in the genome and proteome. Molecular diagnostic tests refer to tests intended to detect specific sequences in human genomic samples, such as DNA or RNA, in order to diagnose a particular disease.

Genetics 40

Genetics Gene Expression RNA DNA 40

The Pharma Data

JUNE 26, 2021

The RECOVERY Actemra/RoActemra study was led by researchers in the United Kingdom and included more than 4,000 hospitalised COVID-19 patients. The RECOVERY Actemra/RoActemra study was led by researchers in the United Kingdom and included more than 4,000 hospitalised COVID-19 patients. Actemra/RoActemra has not been approved by the U.S.

Clinical Trials 40

Clinical Trials Clinical Trials In-Vitro Antibody 40

The Pharma Data

JULY 23, 2021

The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act. “Ronapreve has been shown to improve survival in high-risk, non-hospitalised COVID-19 patients by reducing the risk of hospitalisation and death.

Antibody 52

Antibody Medicine Production In-Vitro 52

The Pharma Data

SEPTEMBER 16, 2020

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Join this event on Roche’s LinkedIn page here. Roche highlights featured at ESMO Virtual Congress 2020.

HR 52

HR Medicine Hormones Trials 52

pharmaphorum

MARCH 15, 2022

The TruSight Oncology in vitro diagnostic (IVD) test is being launched first in Europe and according to Illumina’s cancer head Kevin Keegan can match patients with suitable therapies “according to clinical guidelines or clinical trials, based on their tumour profile.”

Gene 52

Gene Genome Genomics Gene Sequencing 52

Roots Analysis

MARCH 16, 2023

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. mRNA drugs are considered to offer an effective alternative to gene therapies, specifically for protein replacement, as they avoid the risk of genome integration and offer strong transient expression.

Vaccination 52

Vaccination Vaccine DNA Protein 52

XTalks

MAY 12, 2022

This diagnostic assay works on the principle of in vitro nucleic acid amplification using real-time transcription-mediated amplification (TMA) technology. The Aptima CMV Quant Assay helps to detect changes in the viral load of the transplant patient to understand the response of the individual to anti-CMV treatment.

In-Vitro 52

In-Vitro DNA Development Genomics 52

XTalks

NOVEMBER 19, 2021

Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. They can be used in patient selection, stratification, risk mitigation and assessment of safety and efficacy endpoints.

Clinical Trials 94

Clinical Trials Clinical Trials Trials In-Vitro 94

The Pharma Data

JANUARY 24, 2021

It will be run through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), with support from the Bill & Melinda Gates Foundation. Brilacidin has shown in vitro to be have antiviral properties against different SARS-CoV-2 strains and other human coronaviruses. It also has robust antimicrobial properties.

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

MARCH 26, 2021

New in vitro data from pseudotyped virus assays published online in bioRxiv in March 2021 support this hypothesis as they demonstrate that VIR-7831 maintains activity against current circulating variants of concern including the UK, South African and Brazilian variants. About the VIR-7831 Clinical Development Programme.

Antibody 52

Antibody Trials Vaccination Vaccine 52

Pharmaceutical Technology

FEBRUARY 20, 2023

Hans Bunschoten, chief strategy officer, Cerba Research: “Cerba Research and Viroclinics-DDL have a lot of synergies” The discrepancy is magnified in pivotal studies with a 76.1% This may sound obvious, but it is still a major hurdle in drug development. of the clinical trial population globally.

Research 130

Research Clinical Trials Clinical Trials Trials 130

XTalks

NOVEMBER 20, 2020

Researchers at Adaptive Biotechnologies compared T-Detect to a commercial antibody test from DiaSorin on samples obtained from people in Vo’, Italy. A new type of test based on detection of activated T cells may prove to have greater utility in determining whether someone has had a COVID-19 infection compared to a traditional antibody test.

Antibody 98

Antibody Immune Response Protein In-Vitro 98